Medios Ag · XETR:ILM1
Medios — KeplerCheuvreux Digital SMID Mega Trend Days (May 2021)
16 slides from Medios's conference presentation, May 12, 2021
Slide 1: KeplerCheuvreux Digital SMID Mega Trend Days
KeplerCheuvreux Digital SMID Mega Trend Days Matthias Gaertner CEO/CFO May 12, 2021
Slide 2: Medios – The leading Specialty Pharma provider in Germany
Introduction Medios – The leading Specialty Pharma provider in Germany Specialty Pharma: Individualized medicine, treatment of chronic and/or rare diseases, mostly time and cost intensive PATIENT-SPECIFIC THERAPIES Consolidated Revenue in €m FY 2020 EBT2 split 1,150-1,200 - Strongly positioned in pa
Slide 3: Broad specialty pharma product portfolio to address €17.6 bn market opportunity in Germany
Introduction Broad specialty pharma product portfolio to address €17.6 bn market opportunity in Germany in 2021 Infusion Blistering Finished medicinal drugs e.g., ~ 1.6 million cancer patients2 in e.g., ~ 6,600 nursing homes in e.g., ~ 450k2 Hepatitis C patients in Germany Germany4 Germany5 Product
Slide 4: Strong underlying drivers for future market growth
Market environment Strong underlying drivers for future market growth DEVELOPMENT OF NEW ACTIVE PATIENT-SPECIFIC MEDICINE DEMOGRAPHIC CHANGE PHARMACEUTICAL INGREDIENTS Diagnostics and therapies are increasingly individualized – Considerable increase in chronic New therapies mainly focused on impact
Slide 5: Specialty pharma drugs are driving the dynamic market development in Germany
Market environment Specialty pharma drugs are driving the dynamic market development in Germany REVENUE OF PHARMACIES IN GERMANY 2019 Pharmacies revenue in Germany (in € bn)¹ 54.2 50.8 49.1 €54.2bn Total revenue¹ 47.8 48.2 45.8 +6.7% yoy 44.6 thereof 2013 2014 2015 2016 2017 2018 2019 €44.3bn Rx dru
Slide 6: Medios is a highly specialized partner for specialty pharma drugs with a strong partner network
Market positioning & business model Medios is a highly specialized partner for specialty pharma drugs with a strong partner network across Germany INDICATION SPECIFIC PARTNERS Around 500 specialized partner pharmacies nationwide (as of January 2021) Coverage of the entire specialty pharma market: va
Slide 7: Pharmaceutical Supply: 'Classic' trading structure of full-range wholesale
Market positioning & business model Pharmaceutical Supply: ‘Classic’ trading structure of full-range wholesale Pharmaceutical Company 1 Pharmaceutical Company 2 Pharmaceutical Company 3 PHOENIX ALLIANCE SANACORP GEHE NOWEDA ~19,000 pharmacies Standard condition agreements on the entire range of prod
Slide 8: Pharmaceutical Supply: Medios' innovative trading structure
Market positioning & business model Pharmaceutical Supply: Medios’ innovative trading structure Pharmaceutical Company 1 Pharmaceutical Company 2 Pharmaceutical Company 3 ~ 1,000 specialized pharmacies Individual conditions agreement at individual product level max. 1,000 specialty pharma drugs 8
Slide 9: Pharmaceutical Supply: Medios is highly focused and highly efficient
Market positioning & business model Pharmaceutical Supply: Medios is highly focused and highly efficient PHARMACIES IN GERMANY PRODUCT RANGE DISTRIBUTION SYSTEM MARKET POTENTIAL1 100,000 20 €44.3bn 19,000 ~33% ~5% 1% 10% €14.6bn 1,000 1,000 2 All Highly Full Specialty Regional Central Rx drugs2 Spec
Slide 10: Medios is strongly positioned in the competitive market environment
Market positioning & business model Medios is strongly positioned in the competitive market environment WHOLESALE COMPANIES MANUFACTURING COMPANIES • Full-line wholesalers (approx. 100,000 • Mainly regional focus products) • Primarily manufacturers, • Primarily a logistics partner not not consulting
Slide 11: Proven financial track with strong profitable growth
Key financials Proven financial track with strong profitable growth Medios Group IFRS 20161 20172 20182 20192 20202 2021E2 1,150- Pharmaceutical Supply 1,200 Patient-specific Therapies 627 517 10% 10% 328 254 160 12% 90% ++++ 17% 90% 25% 88% 83% Revenue in €m 75% 31-32 Pharmaceutical Supply Patient-
Slide 12: Good plan for organic growth and M&A
Growth strategy Good plan for organic growth and M&A • Establish new labs in Berlin by the end of 2021– to • Ongoing M&A focusing on be able to triple manufacturing capacities • Compounding - increase in capacities for • Expand “blistering” focusing on high-priced drugs enhanced production of indivi
Slide 13: ESG strategy well under way
Sustainability ESG strategy well under way • Code of conduct published end of 2020 • Implementation of ESG targets in the compensation system of the Executive Board • For the first time publication of • Develop and establish ESG strategy, focus on: “voluntary report” based on CSR-RUG¹ • Environmenta
Slide 14: Contact
Contact Claudia Nickolaus Head of Investor & Public Relations Phone: + 49 30 232 566 800 ir@medios.ag 14
Slide 15: Disclaimer
Disclaimer This presentation has been produced by Medios AG (the „Company“). The facts and information The forward-looking statements, including but not limited to assumptions, opinions and views of contained herein are as up to date as is reasonably possible and are subject to revision in the the C
Slide 16: KeplerCheuvreux Digital SMID Mega Trend Days
KeplerCheuvreux Digital SMID Mega Trend Days Matthias Gaertner CEO/CFO May 12, 2021
Medios — KeplerCheuvreux Digital SMID Mega Trend Days (May 2021) on 6ix